0
Archived articleThis is an archived article from 2009 - please note that any content within the article may be out of date.

Hybridan Small Cap Wrap featuring Alliance Pharma, Max Petroleum, Faroe

Hybridanheader.png

This week: A pharma aspirin’ to profit from an acquisition, a bus operator that’s just the ticket, and a public relations outfit boosted by key media trends

Alliance Pharma (APH, 17.5 p / £33.8m)

The speciality pharmaceutical company, with its own brand of aspirin, a range of emollients and other over-the-counter products that can be found on pharmacy shelves, has now completed the acquisition of the worldwide rights to the Buccastem and Timodine brands from Reckitt Benckiser for a total consideration of £7.5m, of which £3.8m is payable in cash. In 2008, total sales of the two brands were £2.6m, which means that Alliance has paid 1.5x sales in cash and the total gross margin of the two brands was 85 per cent, which makes it incredibly interesting to Alliance Pharma. The acquisition is expected to be significantly earnings enhancing in the first full year. Alliance Pharma’s shares have increased fivefold this year.

Angel Mining (ANGM, 2.9p / £7.1m)

The company formerly known as Angus & Ross has issued a $12.5m convertible loan note to a subsidiary of Cyrus Capital Partners following shareholders’ approval. Cyrus now controls 70 per cent of the company but the new funding makes it possible for Angel to go ahead with its two projects in Greenland, the Black Angel zinc/lead mine being the most substantial one.

Ark Therapeutics (AKT, 48.0 p / £99.4m)

The specialist healthcare group announced its results for the first half of 2009 on Wednesday. It has been a busy six months, and progress has been made on its development and commercial activities. Revenues of £0.67m were derived from the wound care division and grew by 61 per cent (H108: £0.41m), reflecting the successful launch of KerraMax in H208 and the strong growth in Flaminal and Kerraped sales. The focus, however, is currently on the European Medicine’s Agency’s (EMEA) consideration of the Cerepro filing for brain tumours, which is currently on a named patient supply basis in France and Finland. The first results of Cerepro phase III trial showed good results and the EMEA is expected to make a decision as to whether Cerepro receives marketing approval by the end of 2009. This will be big news for the company. During H2 09 we should also see the Phase I/IIa study in peripheral vascular disease start in Finland and we also expect to see interim results for the Vitor Phase III pilot trial. Ark had £28.6m of cash at 30 June 2009 and has a number of potentially cash generative discussions ongoing regarding its IP and exploitation of Cerepro in non-core territories.

Ark separately announced that its programme EG011 is commencing Phase I/IIa clinical development for the treatment of refractory angina, which is a large market with significant unmet clinical need. Refractory angina manifests itself as a chest pain because of insufficient oxygen delivery to the heart muscle, usually following recovery from a heart attack. EG011 treatment is expected to increase the blood supply to these areas, thereby improving heart function and subsequent patient mobility.

Ark has five marketed devices in its wound care division and three pharmaceutical products in late stage clinical development: Cerepro, Vitor, and Trinam. We like this company as it has a novel mix of high-class and innovative R&D as well as products that are generating sales. It should appeal to investors as it moves into a commercial, revenue-generating phase.

The CEO, Nigel Parker, yesterday told journalists that “the company plans similar early-stage trials of two other experimental products: one to help surgery for peripheral vascular disease, or loss of blood flow to a limb, and one for foetal growth retardation.”

What is interesting is that these projects will use the same virus-based delivery system Ark developed for its flagship cancer treatment, Cerepro, which regulators are now familiar with. Now is the time to climb aboard the Ark.

Chime Communications (CHW, 171p / £97.6m)

Chime continues to make the right noises. Despite a savage recession, the public relations and marketing services group posted organic operating income growth of 7 per cent and EPS growth of 5 per cent in the six months to 30 June. This was driven by an increase in digital business and in work for national governments seeking to boost their countries’ international trade (a form of ‘public sector’ spend that is relatively resilient to macroeconomic pressures). As Chairman Lord Bell reminded us at the analysts’ briefing, Chime is supported by a diversified business model, with activities spread across a range of sectors and disciplines, so that underperformance in one area can be offset by a strong performance in another.

We continue to believe that PR is an attractive marketing sector, less exposed to cyclical pressures than mainstream advertising, and that it is benefiting from media fragmentation across channels and platforms, in which mass-market advertising has become less effective. It is also benefiting from the increased threat to the reputations of companies and brands posed by the blogosphere, in some cases by advising firms how to alter their activities to counter negative blogs. Indeed, the group’s corporate social responsibility work was described by Lord Bell as a ‘roaring success’.

Faroe Petroleum (FPM, 80.3p / £84.1m)

The oil and gas company focusing on exploration and appraisal in the North Sea and Norway has been on the up since we wrote on it a month ago, and was up another 10 per cent on Wednesday following further good news that drilling has commenced on the Glenlivet prospect (10 per cent owned by Faroe). Chief executive Graham Stewart said that Glenlivet, west of the Shetlands, ‘is an exciting high impact exploration prospect’. It is part of a 2009 two well drilling programme that Faroe is currently undertaking in this area. The other west-of-Shetland well scheduled to drill this year is the Tornado exploration well, about which a further announcement is expected.

Today, Faroe also announced that it had completed the disposal of its entire 10 per cent interest in the Breagh Gas Field in the UK Southern North Sea Gas basin to RWE, for approximately $41.6m. Faroe will book a gain on disposal of approximately £16.7m.
Faroe has a total of nine firm and funded well exploration programmes to be drilled in the next 24 months. Its joint venture partners include household names such as BP, Chevron, ConocoPhillips, E.ON Ruhrgas, Shell and Statoil. The group seeks to reduce its exploration cost exposure whilst retaining material interests, and is well worth a look.

Lombard Risk Management (LRM, 5p / £6.8m)

The second largest global provider of specialist software that improves the management of collateralised trading and regulatory compliance last week announced the appointment of Keith Butcher as finance director from 1 September 2009. Mr. Butcher, aged 46, was previously finance director and company secretary of Flomerics and, before that, finance director of DataCash – both successful AIM-listed technology businesses. He will replace Jane Fineman, who will be stepping down from the position of chief financial officer and leaving the company. We believe Lombard is entering an exciting period in its development, as financial institutions must increase their spend in the regulatory area, and Mr. Butcher’s experience in AIM-listed technology companies is vital at a time when Lombard needed to make the move from a part-time to full-time finance director. We like Lombard Risk for its potential in the collateral management area (Colline), where we expect to see a number of contract wins in the short to medium term.

Max Petroleum (MXP, 25p / £91.3m)

Max Petroleum has secured some much-needed liquidity to continue the exploration of giant sub-salt fields in Kazakhstan. Macquarie Bank has increased its loan commitment to $80m, and this will allow Max to drill 10-15 wells on its Block A&E licence in the fourth quarter of 2009. The good news comes at the expense of shareholders, however, due to massive dilution. Macquarie received warrants to subscribe for 244m shares at 5p per share and would own 48 per cent of the company if fully exercised along with its other holdings. This compares to the current share count of 365m and share price of 25p. The loan still has to be repaid in three installments during the next 18-24 months, while the company’s strategic plan calls for an active drilling programme in the next few years, requiring large additional amounts of capital. There is no doubt that Max has some very significant prospects, but drilling success is now paramount in order to improve the company’s financial position.

Pinewood Shepperton (PWS, 149.5p / £68.6m)

The iconic studio brand, whose illustrious history includes, providing studio facilities for the Carry On films and Superman The Movie, has been going through a tough episode. The group saw revenues decline by 6 per cent, to £20.3m, due partly to the US Screen Actors Guild dispute, which impacted the film division. But revenues held up well in the television division and at the Media Park (which offers property facilities to media companies and now houses 305 business tenants).

Profit before tax, however, declined by a dramatic 55 per cent, to £1.7m. This was largely down to increased interest payments following a rise in net debt and to the fact that the group has relatively high fixed costs, which must be met in full even when revenues fall. Even so, Pinewood Shepperton has around £117m in property, plant and equipment – a set of assets that could rival those of Marilyn Monroe. As such, and despite the difficult economic environment, Pinewood Shepperton’s business could well be set for a happy ending.

ReGen Therapeutics (RGT, 3.6p / £1.1m)

ReGen is a very small company but enjoys a loyal following with shareholders and customers alike. There have been a series of fund raisings this year and last week, the company has placed shares with existing shareholders, many of whom will be delighted to learn that its nutraceutical product, Colostrinin, will soon be available to retail customers in the UK. ReGen has made an agreement with PRG Nutraceuticals for a test marketing programme of Colostrinin under the name MemoryAid, starting in mid-September. If you can’t remember that, you can always bookmark memoryaid.com
as a simple aide memoire – and some might even buy a few shares!

Rotala (ROL, 40p / £10.8m)

The bus operator with hubs in the Midlands, Bristol and West London, this week reported results for the six months to 31 May 2009. It revealed 16 per cent growth in turnover, to £18.3m, and EPS of 3p (H108: 2.83p). Rotala generated cash from operations of £1.7m and reported significant new contract wins. Trading in the year to date continues to be in line with market expectations, which are for Ebitda of £6.4m on revenues of £42m. It is the board’s intention to initiate the payment of dividends this financial year. Rotala is well-established as at least the number two operator in each of its geographic areas of operation. As such, the group is well positioned to benefit from further growth in these areas. Rotala’s model is predicated on establishing local hubs (the bus depots) by acquisition and then expanding organically out from these hubs at low marginal cost.    

The business has strong recurring and visible revenues and bus travel seems to be one area that’s prospered during the recession. So Rotala indeed has a ticket to ride.
Solomon Gold (SOLG, 9.9p / £8.4m)

After several recent fundraisings Solomon has been busy putting the money to work in the field. In an exploration update it presented some preliminary results from mapping, sampling and trenching activities and from an airborne electromagnetic survey. These include several instances of high- grade copper results, newly recognised gold prospects and indications of new porphyry targets. Further sampling and data interpretation are ongoing and support extensive new drilling programmes. A lot more work lies ahead but the company is working towards uncovering another giant gold/copper porphyry system in the region.

TyraTech (TYR, 25p / £5.4m)

TyraTech, the company that makes natural insecticides, has expanded its agreement with the global agrochemical company Arysta Life Science to include a broader range of products and a more rapid market introduction. TyraTech will provide its natural active ingredients to Arysta, who will develop a wide range of agricultural and horticultural insecticides, nematicides and fungicides for exclusive use in the North American markets. Arysta will fund the development and registration costs and the first product is expected to be launched later this year. After a number of disappointments, TyraTech now needs to prove that its relationships with partners Terminix, Arysta and eventually Kraft Foods will provide the big sales volumes that its highly appealing products deserve.

Disclaimer

This is not financial advice. Our content is intended to be used and must be used for information and education purposes only. Please read our disclaimer and terms and conditions to understand our obligations.

No comments yet


No one has commented here yet! Why not be the first one?

Get the free newsletter